BioAlliance Pharma Extends and Strengthens the Protection of AMEP® With the Grant of Two Patents in the US

Published: Jul 12, 2012

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces two key achievements in the development of its biotherapy AMEP® with the decision of granting two patents by the USPTO (United States Patent and Trademark Office).

Back to news